PLX-200
CLN2 Batten Disease (Neuronal Ceroid Lipofuscinosis Type 2)
Phase 1/2Active, Recruiting
Key Facts
Indication
CLN2 Batten Disease (Neuronal Ceroid Lipofuscinosis Type 2)
Phase
Phase 1/2
Status
Active, Recruiting
Company
About Polaryx Therapeutics
Polaryx Therapeutics is dedicated to discovering and developing innovative treatments for devastating rare neurological disorders, with a primary focus on Batten disease and related lysosomal storage diseases. The company's approach centers on small molecules that enhance cellular clearance mechanisms to reduce toxic accumulations in neurons. With a lead candidate in clinical development and a public listing providing capital, Polaryx is positioned to advance its pipeline toward potential regulatory approvals. The company's strategy combines targeted drug development with potential platform expansion into other neurodegenerative conditions.
View full company profile